ERRATUM

Erratum to: Advancing drug delivery systems for the treatment of multiple sclerosis

Inna Tabansky¹ · Mark D. Messina^{2,3} · Catherine Bangeranye³ · Jeffrey Goldstein^{2,3} · Karen M. Blitz-Shabbir² · Suly Machado^{2,3} · Venkatesh Jeganathan⁴ · Paul Wright² · Souhel Najjar² · Yonghao Cao⁴ · Warren Sands^{5,6} · Derin B. Keskin⁷ · Joel N. H. Stern^{1,2,3,4}

Published online: 19 February 2016
© Springer Science+Business Media New York 2016

Erratum to: Immunol Res (2015) 63:58–69 DOI 10.1007/s12026-015-8719-0

Unfortunately, the author names were incorrect in the Reference 86 in the original publication of the article. The corrected reference [86] is given below.

Reference

86. Price JD, Hotta-Iwamura C, Zhao Y, Beauchamp NM, Tarbell KV. DCIR2 + cDC2 DCs and Zbtb32 restore CD4 + T cell tolerance and inhibit diabetes. *Diabetes*. 2015;64:3521–31.

The online version of the original article can be found under doi:[10.1007/s12026-015-8719-0](https://doi.org/10.1007/s12026-015-8719-0).

✉ Joel N. H. Stern
jstern01@rockefeller.edu; joel.n.stern@hofstra.edu

- ¹ Department of Neurobiology and Behavior, The Rockefeller University, New York, NY, USA
- ² Department of Neurology, Hofstra North Shore-LIJ School of Medicine, Hempstead, NY, USA
- ³ Department of Science Education, Hofstra North Shore-LIJ School of Medicine, Hempstead, NY, USA
- ⁴ Department of Autoimmunity, The Feinstein Institute for Medical Research, North Shore-LIJ Health System, Manhasset, NY, USA
- ⁵ School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, USA
- ⁶ Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
- ⁷ Department of Cancer Immunology and AIDS, Dana Farber-Harvard Cancer Institute, Boston, MA, USA